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Background: Fluid retention is a common complication of critical illness. It typically results from large-volume fluid
infusions during acute resuscitation and is worsened by hypoalbuminemia. Recognized as edema, fluid retention is
important for its association with delayed weaning and increased mortality. The standard treatment is the
administration of diuretics, with or without albumin. We hypothesize that intravenous 25% albumin plus furosemide,
by comparison with furosemide alone, improves diuresis, oxygenation, and hemodynamic stability in the
deresuscitation of critically ill, hypoalbuminemic patients. We propose a pilot study to determine the feasibility
of a trial to investigate this hypothesis.
Methods/Design: FADE is a single-center, parallel, pilot randomized controlled trial. We aim to allocate 50
hemodynamically stable, hypoalbuminemic adult patients receiving diuresis to treatment with either 100 ml of
either 25% albumin or normal saline placebo twice daily, for a total of six doses. Diuretics are to be prescribed by
the caregiving team at least twice daily, and administered within 2 hours following study treatment. Patients,
intensive care unit (ICU) clinicians, data collectors, and outcome adjudicators will be blinded to treatment allocation.
Feasibility outcome measures include the proportion of patients receiving albumin within 2 hours of diuretic, the
proportion of patients receiving the full six doses of study treatment, the proportion of patients who receive open label
25% albumin, and the rate of recruitment. Physiologic, laboratory, and clinical data are collected until discharge from
the ICU or until 30 days.
Discussion: This is the first randomized trial to assess the use of hyperoncotic albumin in addition to diuretics in a
general ICU population. Should this pilot study demonstrate feasibility, the primary outcome measure of the larger
clinical trial will be the number of ventilator-free days, with secondary clinical outcome measures of duration of
mechanical ventilation, length of ICU stay, episodes of hemodynamic instability and mortality. The addition of 25%
albumin to standard diuretic therapy is a promising treatment in the post-resuscitation care of the critically ill
patient.
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Study rationale
Many intensive care unit (ICU) patients require fluid re-
suscitation with crystalloids, colloids, or blood products
in order to treat their critical illness. However, aggressive
resuscitation can lead to fluid overload, characterized by
peripheral and pulmonary edema, and has been associ-
ated with the development of acute respiratory distress
syndrome (ARDS) and longer stays in the ICU, as well
as higher mortality, compared with patients without fluid
overload [1-3]. Observational data suggest that positive
fluid balance is among the most important prognostic var-
iables for ICU mortality [4], and a retrospective review of
the use of intravenous fluids during the first four days of
sepsis care in the VASST study showed that a more posi-
tive fluid balance at both 12 hours and day 4 correlated
significantly with mortality [2]. In the ARDS population,
positive fluid balance in addition to a high tidal volume
ventilatory strategy is associated with worse outcomes
[3], and randomized controlled trial data from Wheeler
et al. [5] has shown a conservative intravenous fluid
strategy to be of benefit with respect to improved lung
function and duration of mechanical ventilation strategy
in a broad population with ARDS. More recent data
have suggested that in patients with acute lung injury
complicating septic shock, adequate initial fluid resusci-
tation coupled with conservative late fluid management
results in optimal outcomes [6]. Thus, in ICU patients
without shock, maintenance of euvolemia and diuresis
of excess fluid received during initial resuscitation may
be beneficial, with loop diuretics such as furosemide be-
ing the standard therapy.Table 1 Studies evaluating 25% albumin vs. placebo for the d
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Randomized trials highlighted in bold text. ADO2, alveolar-arterial oxygen differenceAt the same time, critical illness and malnutrition can
lead to hypoproteinemia, resulting in lower vascular onco-
tic pressure and a tendency for fluid to shift into the
interstitial compartment, further worsening edema [7].
For such patients, a strategy of hyperoncotic colloid in-
fusion followed by a diuretic such as furosemide makes
physiologic sense, as the colloid promotes redistribu-
tion of fluid from edematous peripheral tissues back
into the vascular compartment, where it can then be
filtered and excreted by the kidneys. Research from our
institution has confirmed that hyperoncotic albumin
can improve colloid osmotic pressure in critically ill
patients [8]. Furthermore, furosemide itself is heavily
protein-bound, and in hypoproteinemic patients this
results in an increased volume of distribution and lower
concentrations of the diuretic in the loop of Henle [9].
The addition of albumin to furosemide has been shown to
improve the volume of diuresis in several patient popula-
tions, including patients with renal failure [10-12], and cir-
rhosis [13].
Thus, in critically ill patients with hypoproteinemia
and evidence of volume overload, there is a rationale for
studying the addition of colloids to standard diuretic
therapy. Despite this, there are few prospective studies,
and only two randomized controlled trials, which have
evaluated the addition of colloids to diuretics in critically
ill patients (Table 1) [14-17]. Both randomized con-
trolled trials evaluated the use of albumin in addition to
furosemide. Makhoul and colleagues [18] randomized 30
mechanically ventilated patients with congestive heart
failure to intravenous furosemide with or without 25%
albumin, and did not demonstrate a difference in volumeiuresis of critically ill patients
ervention Study outcome
albumin (n = 8) versus
e alone (n = 5); all
ceived furosemide
Improved oxygenation as
measured by ADO2 at 2 hours
nts received 25% albumin;
tients did not; all patients
urosemide infusion
No change in urine output
or fluid balance
rusemide diluted in
umin at a rate of 0.1 mg
e/kg/hour versus furosemide
lone
No difference in urine output
or fluid balance at 24 hours
nts (n= 30) received at
oses of 100 ml 25% albumin;
tients (n= 25) received no albumin
No change in oxygenation,
hemodynamics; higher positive
fluid balance in cases
f 25% albumin every 8 hours
acebo; furosemide infusion
Improved oxygenation, greater
net negative fluid balance, better
maintenance of hemodynamic
stability
nts (n= 57) received 200 ml
umin and Lasix infusion;
tients (n= 57) received usual care
Lower net fluid balance, shorter ICU
stay, reduced duration of mechanical
ventilation; lower mortality
; ARDS, acute respiratory distress syndrome; ICU, intensive care unit.
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although this may be due to the short (24-hour) course of
treatment and the crossover study design. Furthermore,
they did not report clinical outcomes [18]. Martin et al.
[19] studied 40 mechanically ventilated patients with
ARDS, and found that the addition of intravenous albumin
to an infusion of furosemide, compared with furosemide
infusion alone, is beneficial in patients with ARDS, result-
ing in improved volume of diuresis and improved oxygen-
ation, as well as improved hemodynamic stability during
diuresis [19]. In summary, there is promising, but incon-
clusive, evidence available to guide the use of albumin in
addition to diuretics in a general ICU population.
The need for well-studied therapies to treat fluid over-
load in ICU patients therefore warrants a randomized
controlled trial to evaluate the effectiveness of intraven-
ous 25% albumin plus furosemide, compared with fur-
osemide alone, in achieving improved total fluid balance,
oxygenation, and hemodynamic stability at 72 hours, as
well as improved ventilator-free days. Prior to embarking
upon such a trial, we propose a pilot study to assess its
feasibility.Study objectives
Primary objective
To determine the feasibility of conducting a randomized
controlled trial in critically ill patients with hypoproteine-
mia and fluid overload, which will investigate the clinical
effects of 25% albumin in addition to furosemide. Specific
feasibility outcomes, and pre-specified criteria to determine
feasibility, are outlined in Tables 2 and 3.Hypothesis
It is feasible to conduct a randomized controlled trial
in critically ill patients with hypoproteinemia to inves-
tigate the clinical effects of 25% albumin in addition to
furosemide.Secondary objectives
For this pilot study, we will assess feasibility outcomes,
but also collect physiologic and clinical outcome data, in-
cluding volume of diuresis, oxygenation, duration of venti-
lation, length of ICU stay, and mortality. However, we
expect the pilot study to be underpowered to demonstrate
changes in these outcomes. If the pilot study successfully
demonstrates feasibility, these unblinded data will be in-
corporated in the planned larger trial, in a nested fashion.
We hypothesize that the use of intravenous 25% albumin
in addition to furosemide, as opposed to furosemide alone,
increases the volume of diuresis achieved, improves oxy-
genation, prevents intravascular volume depletion at 72
hours, and results in more ventilator-free days.Methods/Design
Study design
The FADE study is a single-center, parallel, pilot ran-
domized controlled trial. The primary outcome is feasi-
bility, with secondary physiologic and patient-important
outcome data also being collected.
Participants
The target population is one of critically ill adults with
hypoalbuminemia who are in a recovery phase of critical
illness and judged by the treating physician to be volume
overloaded, based on clinical findings, such as peripheral
edema, delayed weaning, or chest radiographic findings
of interstitial or pleural fluid. Thus, inclusion criteria
include: (1) admission to ICU; (2) age ≥ 18 years; (3)
hemodynamic stability for at least 24 hours, defined as
the absence of persistent (>1 hour) hypotension (systolic
blood pressure < 90 mmHg) and tachycardia (heart
rate >110), not currently on vasopressors, received less
than 2 l crystalloid or colloid boluses or two units of
packed red blood cells, maintenance fluids excluded;
(4) hypoproteinemia, defined as serum albumin < 30 g/l,
or total protein < 60 g/l; (5) clinical decision by the care-
giving team to diurese at least 3 l of net fluid balance
within the next 72 hours, for any reason.
Patients will be excluded for any of the following reasons:
(1) known pregnancy; (2) patient or surrogate decision
maker unable or unwilling to consent to blood product ad-
ministration, including albumin; (3) acute kidney injury
(RIFLE criteria ‘F’ or greater with either tripling of creatin-
ine or creatinine >355 μmol/l (with a rise of >44) or aver-
age urine output below 0.3 ml/kg/hour for 24 hours)
without any improvement in the previous 24 hours, or
otherwise expected to necessitate dialysis within 48 hours
in the opinion of the treating physician; (4) chronic kidney
injury requiring dialysis; (5) clinically documented cirrho-
sis; (6) clinically documented nephrotic syndrome; (7)
serum sodium levels greater than 150 mEq/l or serum po-
tassium levels less than 2.5 mEq/l that cannot be treated
prior to administration of study treatment; (8) inability to
measure urine output and fluid balance accurately; (9) re-
ceipt of hyperoncotic albumin within preceding 24 hours;
(10) previous enrollment in this trial, or any other re-
search studies for which co-enrollment is not permitted;
(11) estimated survival or ICU stay less than 72 hours.
Recruitment plans and consent process
The study will be carried out at two different ICUs within
a single tertiary care academic center (Hamilton General
Hospital and the Juravinski Hospital and Cancer Centre,
Hamilton, Ontario, Canada). Both sites are research-
intensive and serve a high volume of general medical and
surgical critically ill patients. The recruitment process is
outlined in Figure 1 and Table 4. Patients will be screened
Table 2 Variables, measures, and methods of analysis
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site per week







Increased number of ventilator-free days
in treatment group
Number of ventilator-free days Duration of
ventilation at time
of randomization





Decreased duration of mechanical
ventilation in treatment group










Fewer episodes of interruption in
treatment group
Number of episodes None t test
Need for dialysis Smaller proportion of patients requiring
dialysis in treatment group during ICU
stay
Proportion of patients requiring
dialysis during 30 days
None Chi-squared or Fisher’s
exact statistic
Length of ICU stay Shorter length of stay in treatment
group
Duration of ICU stay Duration of ICU
stay at time of
randomization
t test, linear regression
ICU mortality Decreased ICU mortality in treatment
group during ICU stay




curve (time to death)
30-day mortality Decreased 30-day mortality in treatment
group








Greater increase PaO2/FiO2 ratio in
treatment group at day 3 and day 5
Change in PaO2/FiO2 ratio None t test
Greater decrease in oxygenation index in
treatment group at day 3 and day 5
Change in oxygenation index None t test
Change in lung
compliance
Greater increase in dynamic compliance
in treatment group at day 3 and day 5
Change in dynamic compliance




Greater net decrease in fluid balance in
treatment group at day 3 and day 5
Change in net fluid balance (ml) Net fluid balance at
time of
randomization
t test, linear regression
Change in body
weight
Greater decrease in body weight in
treatment group at day 3 and day 5
Change in body weight (kg) Baseline weight t test, linear regression
Oczkowski et al. Trials 2014, 15:222 Page 4 of 12
http://www.trialsjournal.com/content/15/1/222
Table 2 Variables, measures, and methods of analysis (Continued)
Urine output Greater net urine output in treatment
group at day 3 and day 5
Urine output during 3 days of study
treatment (ml)
Net fluid balance at
time of
randomization
t test, linear regression
Dose of furosemide Lower total amount of furosemide used
in treatment group at day 3





Greater increase in serum albumin level
in treatment group at day 3 and day 5
Change in serum albumin (g/l) None t test
Changes in colloid
osmotic pressure
Greater increase in colloid osmotic
pressure in treatment group at day 3
and day 5





Greater increase in total protein in
treatment group at day 3 and day 5
Change in total protein (g/l) None t test
Change in
electrolytes
No difference between study groups for
major electrolytes (sodium, potassium) at
day 3 and day 5
Change in electrolytes between









Severity of disease Improved hemodynamic stability in







Improved hemodynamic stability in
patients with recent hemodynamic
instability
>48 hours versus <48 hours of















Treatment with albumin results in
improvement beyond that explained by
dose of furosemide
All outcomes Dose of furosemide Multivariable
regression
APACHE-2, Acute Physiology and Chronic Health Evaluation-2; ARDS, acute respiratory distress syndrome; FiO2,, fraction of inspired oxygen; ICU, intensive care unit;
PaO2, partial pressure of oxygen in arterial blood; SOFA, Sepsis-related Organ Failure Assessment.
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ICU. Patients present in the ICU for longer than 72 hours
can be referred to study investigators by the team provid-
ing care if they believe that the patient might qualify for
the study. Patients or surrogate decision makers will be
approached by the research team and informed of theTable 3 Feasibility outcomes and estimated sample sizes
Outcome Demonstration o




Administration of at full 72 hours of study treatment Lower-bound of 9
interval greater tha
Absence of hyperoncotic albumin in control arm Lower-bound of 9
interval greater tha
Randomization rate of patients eligible by screening
criteria
Lower-bound of 9
interval greater thastudy rationale and methods, and provided with literature
about the study. They will then be given an opportunity to
consider study enrollment, in person or via phone. If the
patient is willing, consent for the research study as well as
blood product administration, if it has not already been re-


















Figure 1 Patient recruitment and randomization process. ICU, intensive care unit; IV, intravenously, SDM, surrogate decision maker.
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decides diuresis is necessary, but prior to administering di-
uretics from the caregiving team.
Alternatively, if a treating physician believes that a pa-
tient might qualify for the study, and is in urgent need
of diuresis, the patient can be considered for deferred
consent. To be eligible for deferred consent, patients or
surrogate decision makers must have already given con-
sent for administration of blood products. Patients will
then be randomized to a study arm and diuretics admin-
istered. Study investigators will try to obtain consent
from the surrogate decision maker within the next 48
hours. If the surrogate decision maker cannot be located,
the patient will be withdrawn from the study. Similarly,
if the surrogate decision maker declines participation in
the study, the participant will be withdrawn from the
study. The deferred consent process is only to be used if
the need for diuresis is urgent, and the surrogate deci-
sion maker cannot be reached in a timely fashion.
Many strategies have been implemented to aid in re-
cruitment for this pilot study, including the use of re-
cruitment posters and presentations to familiarize ICU
staff in participating centers with the study aims and
methods. All investigators are either critical care physi-
cians or fellows at the two ICUs where the study is tak-
ing place and will aid in recruitment. The inclusive
eligibility criteria should also facilitate timely completion
of the study.Randomization
The randomization process is outlined in Figure 1. Par-
ticipants will be randomly assigned to either the con-
trol or experimental group in a 1:1 fashion with allocation
concealment using an online computer generated
randomization schedule. Randomization will be done at
the time that the treating physician judges diuresis to be
necessary. Allocation of patients to the study group will be
carried out by the transfusion medicine service, who will
contact a web-based randomization system set up by the
statistics team. The transfusion medicine personnel re-
sponsible for assignment are distinct from the study
personnel enrolling subjects in the study in the ICUs. The
transfusion medicine service will keep an electronic list of
patient names, study ID numbers, and treatment alloca-
tion. Study investigators will not have access to this list
and will have to contact the transfusion medicine service
to unblind patients for any reason, for example, suspected
adverse reaction to a study treatment.
Blinding
Trial participants, care providers, data collectors, and
outcome assessors will be blinded to treatment assign-
ment. Saline placebos will be produced by the hospital’s
pharmacy service under sterile conditions by instilling 100
ml of normal saline into evacuated glass bottles identical
to those used by the manufacturers of the 25% albumin.
The placebos will then be stored in the transfusion
Table 4 Schedule for enrollment, interventions, and assessments
Study period
Enrollment Allocation Post-allocation Close-out
Time point Day −1 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 30
Enrollment
Eligibility screen ×
Deferred or informed consent ×
Allocation ×
Interventions
Treatment arm ×/× ×/× ×/×




Past medical history ×
Type of diagnosis on admission ×
APACHE-2 score at randomization ×
SOFA score at randomization ×
Diagnosis of ARDS at randomization ×
Time since hemodynamic stability ×
Length of ICU stay at randomization ×
Laboratory results
Renal function tests × × × × ×
Serum chemistry × × × × ×
Serum albumin levels × × × × ×
Serum total protein levels × × ×
Colloid osmotic pressure × × ×
Blood gas analysis × × × × ×
Troponin I levels × × × × ×
Serum lactate levels × × × × ×
Complete blood count × × × × ×
Physiologic data
Vital signs × × × × ×
Glasgow Coma Scale rating × × × × ×
Weight × × × × ×
Ventilator data × × × × ×
Fluid intake and output × × × × ×
Diuretic doses and timing × × × × ×
Clinical outcomes
Study treatment held? × × × × ×
Need for dialysis? × × × × × ×
Hypotension requiring fluids × × × × ×
Hypotension requiring vasopressors × × × × ×
Suspected infection? × × × × ×
Intubation status × × × × × ×
Date of transfer from ICU × × × × × ×
Date of death × × × × × ×
APACHE-2, Acute Physiology and Chronic Health Evaluation-2; ARDS, acute respiratory distress syndrome; ICU, intensive care unit; SOFA, Sepsis-related Organ Failure Assessment.
Oczkowski et al. Trials 2014, 15:222 Page 7 of 12
http://www.trialsjournal.com/content/15/1/222
Oczkowski et al. Trials 2014, 15:222 Page 8 of 12
http://www.trialsjournal.com/content/15/1/222medicine department for use in the study. Once a patient
has been randomized and assigned to a treatment group,
the transfusion medicine service will cover the assigned
treatment bottles with an opaque plastic sleeve and dis-
pense them to the ICU, along with opaque intravenous
tubing. Fluids will be infused into direct intravenous ports
rather than distal intravenous tubing so that all study
treatments will be administered directly from the covered
bottles and opaque tubing without intervening clear intra-
venous tubing, which may threaten blinding. The opaque
sleeves and intravenous tubing will allow bedside nurses
to infuse the fluids without compromising blinding of
themselves or the caregiving physicians. To further reduce
bias of reporting, the majority of the outcomes of interest
in the study are objective (that is, laboratory values,
physiologic measurements), rather than subjective out-
comes requiring adjudication.
To ensure the safety of study participants, a protocol
for emergency unblinding exists. In the event of an ad-
verse reaction that could be attributed to the study treat-
ment (for example, anaphylactic reaction or transfusion-
related reaction), the study coordinators will be notified
and will unmask group assignment by communicating
with the third party personnel in the blood bank respon-
sible for group allocation. Code breaks will occur only
under exceptional circumstances. All code breaks (with
justification) will be reported on the relevant case report
forms.Figure 2 Patient treatment and data collection protocol. IV, intravenouInterventions
The treatment and data collection protocol is outlined
in Figure 2. The placebo will be 100 ml of normal (0.9%)
saline, administered as an intravenous infusion twice
daily. This volume is negligible compared with the total
fluid intake of critically ill patients (for feeds, medications,
and so on), and unlikely to adversely affect study or pa-
tient outcomes, but will still provide adequate blinding of
caregivers and study personnel.
The study treatment, either 100 ml of 25% albumin or
100 ml of saline placebo, will be administered as an infu-
sion over 60 minutes, within 2 hours of the patient’s pre-
scribed dose of furosemide. Clinicians will be encouraged
to prescribe furosemide twice daily so as to facilitate the
timely administration of study treatment prior to furosem-
ide administration.
In the event of new or worsening acute kidney injury,
hypotension requiring further boluses of intravenous fluids
or vasopressor agents, or if the caregiving team decides
that further diuresis is unnecessary, study treatment will
be held as long as the caregiving team also holds the fur-
osemide. If a patient’s serum albumin level remains greater
than 35 g/l for two measurements greater than 24 hours
apart, study treatment will likewise be held. Patients will
be monitored for up to 72 hours from randomization and
those patients who the caregiving team decide need fur-
ther diuresis, and have serum albumin levels <35 g/l, will
resume the study treatment to which they were assigned.s.
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to either the albumin, placebo, or furosemide, or the pa-
tient leaves the ICU (is transferred to the ward, another
institution, or dies) study treatment will be discontinued.
No further administration of colloid intravenous fluids
(albumin or starch) will be permitted while the patient is
receiving study treatment. In the event that blood prod-
uct transfusion is required for low serum hemoglobin
levels (as opposed to active bleeding with hemodynamic
instability), one dose of the study treatment may be held
and the prescribed furosemide may be given after the
blood transfusion is completed, at the discretion of the
caregiving team.
Nursing staff will be provided with a bedside schedule
to ensure that the study drug is administered in a timely
fashion and that necessary measurements are performed
and blood samples collected. The short duration of
treatment and the ease of study drug administration will
facilitate adherence across both ICUs.
Outcomes
Outcome measures are detailed in Table 2. Our primary
outcome in this pilot randomized controlled trial is feasi-
bility, which will be assessed using five major feasibility
outcomes: (1) greater than 85% adherence to protocol for
randomized patients, defined as the administration of at
least the first dose of study treatment (albumin or pla-
cebo) within two hours of the first administration of fur-
osemide. This measure was chosen based on the half-life
of serum albumin to increase serum colloid osmotic pres-
sure [8]; (2) more than 80% of randomized patients receiv-
ing the full six doses of treatment study drug; (3) fewer
than 15% of patients receiving non-protocolized hyperon-
cotic albumin administration; (4) recruitment of more
than 50% of patients eligible by screening criteria; and (5)
randomization rate of at least one patients by clinical site
per week.
If all five criteria are met, feasibility will have been de-
termined. Likewise, if the majority (more than three of
five) of the criteria are met, and the unmet criteria could
potentially be addressed with reasonable changes to the
study protocol, feasibility will have been determined. If
the unmet criteria cannot be addressed with changes to
study protocol, or only a minority (one or two of five) of
criteria are met, then non-feasibility will have been
determined.
We will also collect clinical and physiologic outcome
data, in anticipation of conducting a larger follow-up
trial, should this study determine feasibility. The primary
outcome for that trial will be the number of ventilator-
free days from time of randomization. Ventilator-free days
are defined over a 28-day period, with a patient receiving
one ventilator-free day for each 24 hour period spent
without the need for mechanical ventilation. Patients whodie during the 28 days will automatically be assigned 0
ventilator-free days [20]. This is a commonly used out-
come in critical care trials, as it incorporates patient-
important outcomes of duration of mechanical ventilation
and mortality, both of which have been associated with
volume overload in observational studies.
The secondary clinical outcomes that we will collect
data for include: (1) duration of mechanical ventilation,
measured from time of randomization until extubation
that is successful for 24 hours or more, recorded in days;
(2) number of episodes of interrupting treatment with fur-
osemide (for example, hypotensive episodes, renal failure,
contraction alkalosis); (3) proportion of patients receiving
dialysis; (4) length of ICU stay from randomization; (5)
ICU mortality; and (6) 30 day mortality. We hypothesize
that the addition of 25% albumin will lead to fewer inter-
ruptions of diuresis, a reduced incidence of acute kidney
injury, and a shorter stay in the ICU.
The secondary physiologic outcomes that we will collect
data for include: (1) changes in oxygenation (FiO2, PaO2/
FiO2 ratio, oxygenation index) from baseline at day 3 and
day 5; (2) changes in dynamic lung compliance, reflecting
changes in extravascular lung water, at day 3 and day 5;
(3) changes in total fluid balance and body weight, and
amount of urine output from baseline at day 3 and day 5;
(4) total dose of furosemide used, to assess whether study
treatment improves the physiologic response to furosem-
ide; (5) changes in serum albumin and colloid osmotic
pressure between treatment groups from baseline at day 3
and day 5, to ensure that the experimental treatment re-
sults in the expected increases in these measurements; (6)
changes in electrolyte levels (potassium level less than 2.5
mEq/l, sodium level >150 mEq/l), as a way to ensure that
no major, potentially harmful changes in serum electro-
lytes occur as a result of study treatment.
Sample size calculations
We determined that the greatest threat to the feasibility
is the ability to administer the first dose of study treat-
ment in a timely fashion, within two hours of the first
administration of furosemide. As such, it was selected as
the outcome used to determine our sample size. Assum-
ing an actual adherence of 92.5%, to demonstrate at least
an 85% adherence, a sample size of 47 is required. Other
important feasibility outcomes include the administration
of 72 hours of study treatment to each patient, and the ab-
sence of hyperoncotic albumin administration in the con-
trol arm. Estimated sample sizes required to show those
outcomes with the desired level of precision are shown in
Table 3.
Data collection
Data to be collected are listed in Table 4. Demographic
information, prior medical conditions, and reason for
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and Chronic Health Evaluation (APACHE), and Sepsis-
related Organ Failure Assessment (SOFA) will be used at
the time of ICU admission, the time of randomization,
and the treatment end. The administration and doses of
intravenous fluids, blood products, and diuretics will also
be recorded. Data related to rationale for diuresis will also
be collected (peripheral edema, pulmonary edema on
chest X-ray, low urine output, elevated central venous
pressures or left atrial pressures). Study outcome data col-
lected daily will include vital signs and hemodynamics (if
central venous monitoring or pulmonary artery catheters
are in place), fluid balance, hourly urine output, weight,
ventilator settings (if patient is ventilated), intubation sta-
tus (including reasons for intubation or re-intubation),
oxygenation parameters (SaO2, FiO2, PaO2/FiO2 ratio,
oxygenation index). Blood samples, to determine standard
and extended electrolyte levels, renal profile, complete
blood count with differential, serum albumin and total
protein levels, and blood gas data, are routinely collected
in patients undergoing diuresis and will be collected at
least daily. Colloid osmotic pressure and serum total pro-
tein will also be assessed at baseline, day 3 and day 5.
Study data will be collected from the time of ICU admis-
sion to hospital discharge or 30 days after enrollment. All
of these data are measured routinely in the ICU and sub-
ject to minimal interobserver variation. Colloid osmotic
pressure will be measured using the Wescor model 4220,
which has a precision of ± 0.03 mmHg [21].
Subject data will be collected daily through examin-
ation of the patient chart, including electronic ICU
charting and the Meditech laboratory reporting system.
Standardized electronic case report forms will be used
to collect patient and study data. Data recording will be
performed using standardized case report forms in du-
plicate to ensure minimal human error. Data from case
report forms will be entered into an electronic database
on a secure computer server. Given the short time of
study treatment (3 days) and intensive follow-up to 5
days, retention of study subjects is not anticipated to
pose a problem. Similarly, longer-term follow-up data
for our outcomes of interest (transfer from ICU, ventilator-
free days, and death) are easily retrieved from hospital
records.
Data management
Data will be entered using electronic case report forms
into a computerized database stored on a secure server
in the Department of Epidemiology and Biostatistics at
McMaster University. All collected data will be kept
under secure conditions in keeping with Good Clinical
Practice and McMaster University’s research ethics
board guidelines for a minimum of 7 years following
study completion.Statistical methods
All P values will be two sided, with a level of P ≤ 0.05 in-
dicating statistical significance. All data will be analyzed
using statistical software on an intention-to-treat basis.
All randomized participants, regardless of protocol ad-
herence, will be included in the main analysis.
Feasibility outcomes will be calculated as proportions
with 95% confidence intervals, with feasibility being met
if the lower-bound of the 95% confidence interval is
above the level pre-specified for feasibility (Table 3).
Data regarding our primary and secondary clinical out-
comes will also be collected during this pilot study for
future analysis; however, no analysis of clinical outcomes
will be made for this pilot study, as the main purpose is
to inform the definitive trial. Data collected from this
pilot study will remain blinded and eventually incorpo-
rated into the dataset for the definitive trial, with the fol-
lowing pre-specified analyses.
Comparisons between the two treatment groups at a
single time point (for example, baseline variables, num-
ber of patients requiring fluid bolus or vasopressors for
hypotension, total dose of furosemide, and so on) will
made using unpaired Student’s t test. Comparisons within
a treatment group at different time points (change in
serum albumin, colloid osmotic pressure, total protein,
weight, fluid balance, oxygenation, lung compliance at day
3 and day 5, and so on) will be analyzed in a similar fash-
ion. Multiple between-groups comparisons of continuous
variables will be analyzed by repeated-measures analysis of
variance. Linear regression will be used where appropriate
to correct for baseline variables. Ventilator-free days will
be defined as the number of 24-hour periods in which a
patient does not need ventilation during 28 days (patients
who die, by definition, will have 0 ventilator-free days).
Survival analysis will be performed to assess 30-day
mortality.
A-priori analyses include stratifying patients by illness
severity at time of randomization (using APACHE and
SOFA scores), presence of ARDS, patients admitted with
sepsis, patients admitted with congestive heart failure,
and time since recovery of hemodynamic stability (greater
than or less than 48 hours from discontinuation of vaso-
pressors). All subgroups carry biological plausibility for
differing effects of the intervention, with the hypothesis
of greater improvement in those patients with more se-
vere illness, presence of ARDS, and shorter time since
hemodynamic stability.
Data monitoring and auditing
Study participants will be closely monitored in the ICU.
Suspected harms of the study treatment will be reported
directly to study investigators. Case report forms will
also be used to record any suspected harms and clinically
important differences between treatment and control groups,
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free days, and electrolyte abnormalities, which will be ana-
lyzed using the statistical methods outlined in Table 2.
Data monitoring and quality assurance of the study will be
undertaken by the investigators. The local investigator
(CH) will undertake responsibility for such duties.
Study participants may be withdrawn from the study
early if there is suspicion of treatment harm by the team
caring for the participant, such as an allergic reaction,
worsening renal function, or worsening hypernatremia;
or if consent for study therapy is withdrawn by the par-
ticipant or surrogate decision maker at any time. Treat-
ing physicians cannot withdraw patients from the study,
but can decide to withhold study treatment. Participants
who withdraw consent to the study will be asked whether
they are withdrawing from any or all of: (1) study treat-
ment, (2) future data collection, or (3) primary outcome
data collection.
Formal data monitoring will not be performed in this
small pilot randomized controlled trial, owing to both its
small sample size and the small risk the intervention
poses to study participants. A formal data-monitoring
committee will be created to oversee the larger follow-
up trial, should this pilot study demonstrate feasibility.
Research ethics approval and confidentiality
The study protocol, written and verbal consent forms,
data to be collected, and recruitment posters have been
approved by the Hamilton Integrated Research Ethics
Board (Project #14-002). Any modifications of the protocol
that might impact patient safety, confidentiality, or other
significant conduct of the study will be reviewed by the
Hamilton Integrated Research Ethics Board before imple-
mentation. Minor administrative changes will be reviewed
by the investigative team but not the Hamilton Integrated
Research Ethics Board.
All study information will be stored securely in locked
cabinets or on secure, password-protected computer sys-
tems with limited access at the study sites. All case report
form data, laboratory specimens, and administration forms
will be identified with a coded identification number to
maintain patient confidentiality. Records containing pa-
tient names and other identifying information will be
stored in a separate locked area with limited access. No
patient-identifying information will be published or re-
leased to anyone outside of the study team.
Access to data
Data management will be performed by members of the
Department of Epidemiology and Biostatistics at McMas-
ter University. The study investigators will have full access
to study datasets. External requests for study data will be
granted, however any information that is shared will be
blinded to any identifying participant information.Ancillary and post-trial care
Patients enrolled into the study will receive routine care
from the intensive care team following completion of study
treatment. Should this study, or its follow-up studies, pro-
vide evidence of the effectiveness, no further provision of
treatment to participants will be required, as the study
treatment is for short-term use only.Dissemination policy
There are no stipulations on publication in place by any
party, including the trial sponsors. The study investiga-
tors will publish the results of the pilot study, including
feasibility outcomes and characteristics of the study co-
hort, should feasibility be demonstrated. Outcomes ana-
lyzed by the treatment group will only be published if
non-feasibility is demonstrated; otherwise pilot outcome
data will be retained for incorporation in the larger
follow-up study. Attempts will be made to accomplish
publication within 6 months of trial completion, and in
keeping with the CONSORT guidelines for randomized
controlled trial publication [22]. Authorship for publica-
tions will be in keeping with guidelines from the Inter-
national Council of Medical Journal Editors [23]. Following
the completion of this pilot study, and the larger, follow-up
study (should this pilot demonstrate feasibility) a com-
pletely de-identified data set will be archived for sharing
purposes.Discussion
The FADE study is the first prospective randomized con-
trolled trial to assess the use of hyperoncotic albumin in
addition to diuretics in a general ICU population. Should
this pilot study demonstrate feasibility, the primary out-
come of the larger clinical trial will be an increase in the
number of ventilator-free days, with secondary clinical
outcomes of reductions in the duration of mechanical
ventilation, length of ICU stay, episodes of hemodynamic
instability, and mortality. The addition of 25% albumin to
standard diuretic therapy is a promising treatment in the
post-resuscitation care of critically ill patients with edema.Trial status
The trial is not yet recruiting.
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